AstraZeneca wins priority review schedule for leukemia drug; Penn gene therapy upstart grabs $9.29M with Frazier’s help – Endpoints News
Endpoints News |
AstraZeneca wins priority review schedule for leukemia drug; Penn gene therapy upstart grabs $9.29M with Frazier’s help
Endpoints News With major help from Frazier Healthcare Partners, a stealthy gene therapy company from the University of Pennsylvania has secured $9.29 million in investment. Gene therapy pioneer James Wilson co-registered the company in 2016, the Philadelphia … |
Huntington’s Disease News |
Immunotherapy Candidates Showing Promise as Potential Ways of Treating Huntington’s
Huntington’s Disease News However, these aggregates are also present in body fluids and extracellular spaces, and a recently developed antibody against free mHTT was able to decrease mHTT levels and improve motor function in a mouse model of the disease. Among the advantages of … |
|
Pfizer Takes On Gilead, Novartis With New Deal In Cancer Drugs
Investor’s Business Daily CAR–T therapies from Gilead and Novartis already are on the market. These drugs are created using a patient’s own extracted immune cells. Scientists reprogram a patient’s cells to fight cancer before returning them to the patient. Pfizer and Allogene … |
Boing Boing |
The astounding present and dizzying future of synthetic biology
Boing Boing George Church’s Harvard lab is one of the most celebrated fonts of innovation in the world of life sciences. George’s earliest work on the Human Genome Project arguably pre-dated the actual start of that project. Subsequently, he’s been involved in the … |